AstraZeneca

Stock performance

History

AstraZeneca was formed in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, itself a 1993 spinoff of Imperial Chemical Industries' pharmaceutical business. The combined company built a broad drug-development pipeline across oncology, cardiovascular, and respiratory disease, and became globally prominent during the COVID-19 pandemic when it partnered with Oxford University to develop one of the first widely distributed COVID-19 vaccines, distributed on a not-for-profit basis during the pandemic in a move that drew both praise for accessibility and scrutiny over manufacturing and supply issues.

Business model

AstraZeneca researches, develops, manufactures, and markets prescription medicines across oncology, cardiovascular and metabolic disease, respiratory conditions, and rare diseases, earning revenue primarily from patented drug sales to healthcare systems and insurers worldwide. Its business depends on sustained heavy investment in drug research and clinical trials, with revenue concentrated in a portfolio of patent-protected medicines that eventually face generic competition once patents expire, requiring a constant pipeline of new drug approvals to sustain growth.

Market position

AstraZeneca is one of the largest pharmaceutical companies in the world by revenue and the largest in the United Kingdom, with a particularly strong position in oncology drugs. It competes with global pharmaceutical majors including Pfizer, Merck, and Novartis, and its oncology and rare-disease pipelines are viewed as key growth drivers as some of its earlier blockbuster drugs face patent expiration.

Country impact

AstraZeneca is the largest company in the UK's pharmaceutical sector and a significant contributor to British life-sciences research and employment, particularly around its Cambridge headquarters, which anchors a broader biotech cluster. Its role in the Oxford-AstraZeneca COVID-19 vaccine made it a household name in the UK and a symbol of British scientific and industrial capability during the pandemic.